Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
We evaluated the effects of amantadine on levodopa-induced dyskinesia (LID) in eighteen consecutive Parkinson's disease (PD) patients in a randomized, double-blind, placebo-controlled study. The primary outcomes were the Clinical Dyskinesia Rating Scale (CDRS) and the Unified Parkinson's Disease Rating Scale (UPDRS) part IVa score changes. The secondary outcomes were the UPDRS II and III score changes. Amantadine did not change the CDRS score for hyperkinesia or dystonia, but decreased the duration of LID and its influence on daily activities (p=0.04) and the UPDRS II score (p=0.01) more than placebo. These findings show that amantadine reduces the duration of LID and improves motor disability in PD.
da Silva-Júnior
Francisco Pereira
FP
Department of Clinical Medicine, Federal University of Ceará, Rua Prof. Costa Mendes 1608 4 Andar, CEP 60430 040, Fortaleza, Ceará, Brazil.
Braga-Neto
Pedro
P
Sueli Monte
Francisca
F
de Bruin
Veralice Meireles Sales
VM
D000368:Aged; D000547:Amantadine / Q000008:administration & dosage* / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D010919:Placebos; D007980:Levodopa; D000547:Amantadine